Summary p21 (WAF1/CIP1) protein expression in various thyroid tissues, including thyroid carcinoma, was studied by means of immunohistochemistry using anti-p21 monoclonal antibody. Normal follicles and hyperplasias rarely expressed p21, whereas immunohistochemically positive cells were also too rarely found in follicular adenomas to justify these cases being classified as positive. Twenty eight of the 93 carcinomas examined (30.1%), however, were positive for p21. Of the p21-positive cases, 80% of the undifferentiated and 28.6% of the poorly differentiated carcinomas showed lesions co-expressing p21 and p53. If diffuse immunoreactivity of p53 reflects the p53 mutation, our results indicate that p21 in these carcinomas can be induced by p53-independent as well as by p53-dependent pathways. On the other hand, well-differentiated carcinomas did not co-express these two proteins and it therefore remains unclear whether p53-independent or p53-dependent pathways are predominant in this type of carcinoma. The incidence of expression of p21 was very similar in undifferentiated (26.3%), poorly (28.0%) and well-differentiated carcinomas (32.7%), even though they are characterised by different degrees of malignancy. Furthermore, no correlation between p21 expression and either clinical parameters or patient's prognosis could be established. These results suggest that p21 is only marginally related to the characteristics of thyroid carcinoma and can play only an adjuvant role in regulating the progression of this carcinoma.
p21 is a protein encoded in the WAFI/CIPI gene on chromosome 6p. This protein constitutes one of the cdk inhibitors and regulates the cell cycle universally (Xiong et al., 1993; Harper et al., 1993; El-Deiry et al., 1993) . Furthermore, it binds to the proliferating cell nuclear antigen (PCNA) to inhibit DNA replication (Flores-Rozas et al., 1994; Li et al., 1994) . WAFI/CIPI was, at first, found to be induced directly by wild-type p53 (El-Deiry et al., 1993) and another report indicated that WAFI/CIPI is transcriptionally activated in p53-mediated GI arrest and apoptosis but not in p53-independent ones (El-Deiry et al., 1994) . These findings suggest that p21 is a downstream effector of p53. On the other hand, a few studies using fibroblasts from p53 knock-out mice (Michieli et al., 1994) , breast carcinoma cells (Sheikh et al., 1994) and human leukaemia cells (Zhang et al., 1995) have shown that p21 is inducible also in a p53-independent manner. Recently, studies of p21 expression in human normal and neoplastic tissues have attempted to elucidate the manner in which this protein effects regulation. El-Deiry et al. (1995) reported that p21-expressing lesions in gastrointestinal tracts were highly compartmentalised and correlated with proliferation, while such compartmentalisation was largely abrogated in colonic neoplasms. This was the first report on immunolocalisation of p21 and similar studies for the pancreas and brain were published subsequently (DiGiuseppe et al., 1995; Jung et al., 1995) . Furthermore, we investigated p21 expression in human breast carcinoma tissues and found that the lack of p21 expression in breast carcinomas was related to prognostic factors, such as lymph node metastasis and histological grade, and that it affects even prognosis itself (Ito et al., 1996) . However, carcinoma progression is not uniform or immediate in every organ. Thyroid carcinoma has two thoroughly polarised characteristics of progression, depending on the pathological type.
Anaplastic (undifferentiated) carcinoma is characterised by exceptionally quick progression with dire prognosis, while other types show slow growth with an excellent prognosis. In this study, we investigated p21 expression in thyroid tissues, including thyroid carcinoma, in order to investigate whether any features of positivity and of manner of expression of this protein in thyroid carcinoma show any of the special characteristics described above. We also investigated the relation between the expressions of p21 and p53 to determine whether p21 is induced by p53-dependent or -independent pathways. (Sakamoto et al., 1983; Carcangiu et al., 1984; Papotti et al., 1993 After blocking with 5% skimmed milk, the membranes were incubated with a primary antibody at a concentration of 10 ,g ml-'. The filters were then washed with TBST (Trisbuffered saline, 50 mM Tris-HCI, pH 7.5, 150 mM sodium chloride) plus 0.1% Tween 20 (Sigma, St Louis, MO, USA), followed by incubation with the second antibody which had been alkaline phosphatase-conjugated. The filters were again washed in TBST and developed with the Proto Blot NBT and BCIP Color Development System (Promeaga, Madison, WI, USA).
Materials and methods
Immunohistochemistry Cultured cells were collected, cytocentrifuged onto poly-Llysine-coated glass slides, immediately fixed in buffered formalin for 1 h, and washed in distilled water for 5 min. Tissue sections were prepared in 4 Mm-thick slices from paraffin-embedded thyroid tumour specimens. The paraffin was then removed in xylene three times, after which the tissues were rehydrated through a graded ethanol series ranging from 100% to 60%. After quenching endogenous peroxidase activity by immersing the sections in 0.3% (v/v) hydrogen peroxidase containing 0.1% (w/v) sodium azide for 30 min, non-specific binding was blocked by treatment with 10% (v/v) normal rabbit serum for 30 min. The primary antibody was applied to the slices and incubation was performed overnight at 4°C in a moist chamber. After washing in 0.01 mol 1-1 phosphate-buffered saline (pH 7.2) (PBS), biotinylated anti-mouse immunogloblin (Histofine SAB-PO kit, Nichirei, Tokyo, Japan) was applied and the slides were incubated for 30 min at room temperature. After a second washing in PBS, peroxidase-conjugated streptavidin (Hiastofine SAB-PO kit) was applied and the slides were again incubated for more than 30 min. The excess complexes were then washed off and the immunoreactivity was visualised by incubating the slides for 5 min in 0.05 mol 1-l Tris-HC1 (pH 7.6) containing 0.02% (w/v) 3,3-diaminobenzidine tetrahydrochloride with 0.03% (v/v) hydrogen peroxide. Tissue sections were counterstained for 3 min in 0.5% methyl green. A negative control for immunohistochemistry of p21 employing normal mouse serum was included in each staining procedure.
Results
To establish the specificity of anti-p21 antibody, we performed Western blot analysis for MCF-7 cells and MDA-MB-231 cells employed as, respectively, positive and negative controls (Sheikh et al., 1994) . The same analysis was used for representative cases of matched pairs of normal and carcinoma thyroid tissues immunohistochemically positive for p21 (Figure 1 ). The result showed that carcinoma tissues as well as MCF-7 cells produced much more intense signals for p21 at 21 kDa than did normal follicles. demonstrated no signals for p21.
Immunohistochemical staining of MCF-7 cells, used as positive control, demonstrated diffuse nuclear staining of p21 (Figure 2a ), whereas p21-positive cells were rarely found among MDA-MB-231 cells (Figure 2b ) (Sheikh et al., 1994) . When various thyroid tissues were subjected to immunohistochemical examination, p21 was rarely detectable in normal follicles and hyperplasias. Some follicular adenoma cells were immunoreactive for p21 but their positive cell rates in each case were less than 10% (Figure 3a) . In 30.1% of the carcinomas, p21-immunoreactive cells were more often observed in scattered and/or compartmentalised configurations. The p21-positive cell rate was usually less than 30% and rarely exceeded 50%. In this study, therefore, we classified the samples as positive when more than 10% of carcinoma cells were immunoreactive. The results for the carcinomas are summarised in Table I al., 1988; Grontajaski et al., 1984) . Normal thyroid follicles and hyperplasias expressed p53 in a highly limited fashion. Figure 3b represents the case which showed p53 immunoreactivity with the highest positivity of all follicular adenomas we examined, but even in this case the positive cell ratio was still very low and much less than 10%. All carcinoma cases classified as positive showed p53 immunoreactivity in the nuclei of the carcinoma cells very diffusely ( Figures Sb and d and 6) . The results showed that p53 overexpression was observed in 16.1% of the carcinomas tested and a statistically significant difference (P<0.01) was found between p53 positivity and carcinoma differentiation (Table III) . Especially noteworthy is that, among WDCs, only one case was classified as p53 positive (Figure 6 ). Table  IV shows the results of immunohistochemical investigation, using serial sections, of co-expression of p21 and p53. Four UDCs and two PDCs, that is, 80% of the p21-positive UDCs and 28.6% of the p21-positive PDCs, had lesions coexpressing p21 and p53 ( Figure 5 ). No co-expressing lesion was observed in any of the WDCs. On the other hand, of the p53-negative cases, one of the eight UDCs (12.5%), five of the 16 PDCs (23.8%) and 16 of the 48 WDCs (33.3%) were positive for p21.
The three patients, two with PDC and one with WDC, first patient 8 and the second 6 months post-operatively. They are scheduled for reoperation. All other patients are still alive with no symptons of recurrence so far.
Discussion
In this study, we investigated p21 expression in various thyroid tissues. In normal follicles, only faint signals were detected by Western blot analysis and p21 immunohistochemically positive cells were rarely found. A previous report proved that p21 can be active as a negative regulator of cell proliferation in some normal organs (El-Deiry et al., 1995) . According to this report, lesions expressing p21 intensely were observed selectively in unreplicative and post-replicative compartments in the gastrointestinal tract epithelia. It is thus suggested that the quantitative level of p21 protein in follicles of the thyroid is definitely lower than in gastrointestinal tract epithelia, probably because the latter can be expected to require much higher levels of p21 expression in order to regulate the active cell replication caused by the rapid metabolism. The observation that, in hyperplasias, p21 levels were as low as in normal follicles seems reasonable, for the entity of this disease is overproduction of thyroid hormones by each cell rather than cell proliferation. Among tumours of the thyroid, none of the follicular adenoma tested showed high levels of p21 protein. It appears that p21 has little clinical significance for follicular adenoma, possibly because it is a benign disease with low proliferation activity, which does not require restriction by p21 overexpression. Concerning the thyroid carcinomas, p21 was often overexpressed, probably in order to control the abnormal cell cycle progression and cell replication of carcinoma cells negatively. However, overexpression or lack of expression of p21 was not related to pathological type, carcinoma differentiation or other clinicopathological parameters such as age, sex and distant (lung) metastasis. These observations suggest that only minor clinical significance can be attributed to this protein in thyroid carcinoma, in contrast to breast carcinoma (Ito et al., 1996) . However, there is a possibility that mutant p21 protein recognised by the antibody we used is expressed more frequently in UDCs or PDCs than in WDCs. Reports on WAFI/CIPI mutation are rare (Shiohara et al., 1994; Li et al., 1995) , but a study of a larger number of UDCs and PDCs is needed to reach a definitive conclusion as to whether p21 in thyroid carcinoma has any clinical significance.
Our observations of p53 expression were mostly consistent with those of previous studies (Donghi et al., 1993; Dobashi et al., 1993; Soares et al., 1994; Holms and Nesland, 1994) except for one (Wright et al., 1991) (Serrano et al.. 1993) . which determine the differences in malignant potential and prognosis of UDC. PDC and WDC. Furthermore. an investigation as to whether there is any difference in p221 and p53 expression between patients exposed to nuclear radiation and those living in a normal environment could add valuable insights to this field of investigation.
